Notes
Costs were presented in 2019 values; a 3% annual discount rate was applied to future costs and benefits.
Reference
Ivanova-Markova Y, et al. Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain. Vaccine : 15 Nov 2021. Available from: URL: http://doi.org/10.1016/j.vaccine.2021.11.006
Rights and permissions
About this article
Cite this article
Invasive meningococcal disease uncommon but a high economic burden for Spain. PharmacoEcon Outcomes News 892, 15 (2021). https://doi.org/10.1007/s40274-021-08210-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08210-z